These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 31909149)

  • 1. Investigating the role of allergic contact dermatitis in residual ocular surface disease on dupilumab (ROSDD)
    Raffi J; Suresh R; Fishman H; Botto N; Murase JE
    Int J Womens Dermatol; 2019 Dec; 5(5):308-313. PubMed ID: 31909149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of dupilumab on patch testing and the prevalence of comorbid allergic contact dermatitis in recalcitrant atopic dermatitis: A retrospective chart review.
    Raffi J; Suresh R; Botto N; Murase JE
    J Am Acad Dermatol; 2020 Jan; 82(1):132-138. PubMed ID: 31562940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variable impact of dupilumab on patch testing results and allergic contact dermatitis in adults with atopic dermatitis.
    Stout M; Silverberg JI
    J Am Acad Dermatol; 2019 Jul; 81(1):157-162. PubMed ID: 30885752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of Residual Facial Dermatitis during Dupilumab Therapy: A Retrospective Chart Review to Delineate the Potential Role of Expanded Series Patch Testing.
    Ashbaugh AG; Murase EM; Raffi J; Botto N; Murase JE
    Dermatitis; 2022 Jan-Feb 01; 33(1):51-61. PubMed ID: 35029349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of dupilumab-associated ocular surface diseases in atopic dermatitis patients.
    Guex-Crosier Y; Di-Lucca J; Häusermann P; Laffitte E; Saulite I; Schmid-Grendelmeier P; Schürch K; Thormann K; Simon D
    Swiss Med Wkly; 2021 Aug; 151():w30020. PubMed ID: 34495603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of ocular disease during dupilumab treatment for atopic dermatitis: a bicentric retrospective comparative cohort study.
    Barbé J; Poreaux C; Remen T; Schoeffler A; Cloché V; Schmutz JL; Escobar G; Busztejn AC
    Int J Dermatol; 2021 Dec; 60(12):1520-1528. PubMed ID: 34037253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case series of dupilumab-treated allergic contact dermatitis patients.
    Goldminz AM; Scheinman PL
    Dermatol Ther; 2018 Nov; 31(6):e12701. PubMed ID: 30246906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Characteristics and Treatment for Dupilumab-Related Ocular Complications in Atopic Dermatitis Patients.
    Tauqeer Z; Jinno SE; Chung CW; Massaro-Giordano M; Bunya VY
    Clin Ophthalmol; 2022; 16():947-958. PubMed ID: 35378901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patch Testing in Patients With Severe Atopic Dermatitis Treated With Dupilumab: A Multicentric Approach in Spain.
    Docampo-Simón A; Sánchez-Pujol MJ; Pastor-Nieto MA; Giménez-Arnau A; Rodríguez-Serna M; Serra-Baldrich E; Miquel J; Sánchez-Pérez J; Sanz-Sánchez T; Zaragoza-Ninet V; Sánchez-Pedreño P; Carrascosa JM; Gatica-Ortega ME; Fernández-Redondo V; Córdoba-Guijarro S; González-Pérez R; Silvestre JF
    Dermatitis; 2023; 34(4):315-322. PubMed ID: 37001174
    [No Abstract]   [Full Text] [Related]  

  • 10. Eye Complications During Dupilumab Treatment for Severe Atopic Dermatitis.
    Ivert LU; Wahlgren CF; Ivert L; Lundqvist M; Bradley M
    Acta Derm Venereol; 2019 Apr; 99(4):375-378. PubMed ID: 30653240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ocular Surface Diseases Induced by Dupilumab in Severe Atopic Dermatitis.
    Maudinet A; Law-Koune S; Duretz C; Lasek A; Modiano P; Tran THC
    Ophthalmol Ther; 2019 Sep; 8(3):485-490. PubMed ID: 31230264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic Dermatitis.
    Achten RE; Van Luijk C; Van der Rijst L; Bakker D; Spekhorst L; Zuithoff N; Schuttelaar M; Romeijn G; Voorberg A; Kamsteeg M; Haeck I; De Graaf M; Thijs J; De Boer J; De Bruin-Weller M
    Acta Derm Venereol; 2022 Mar; 102():adv00666. PubMed ID: 35098318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dupilumab-associated cicatrizing ocular disease.
    Reddy AK; Hauswirth SG; Gregory DG; Liao SD; Palestine AG
    Am J Ophthalmol Case Rep; 2022 Jun; 26():101528. PubMed ID: 35479518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Encounters and medication use for ocular surface disorders among patients treated with dupilumab: A cohort study.
    Barbieri JS; Bunya VY; Massaro-Giordano M; Margolis DJ
    JAAD Int; 2021 Sep; 4():1-9. PubMed ID: 34409381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis.
    Halling AS; Loft N; Silverberg JI; Guttman-Yassky E; Thyssen JP
    J Am Acad Dermatol; 2021 Jan; 84(1):139-147. PubMed ID: 32822798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis.
    Liberman P; Shifera AS; Berkenstock M
    Cornea; 2020 Jun; 39(6):784-786. PubMed ID: 31985517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
    Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
    Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dupilumab after the 2017 approval for the treatment of atopic dermatitis: what's new and what's next?
    van der Schaft J; Thijs JL; de Bruin-Weller MS; Balak DMW
    Curr Opin Allergy Clin Immunol; 2019 Aug; 19(4):341-349. PubMed ID: 31145194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Higher prevalence of dupilumab-induced ocular adverse events in atopic dermatitis compared to asthma: A daily practice analysis.
    Schlösser AR; Bult L; Thelen JC; Thiadens AAHJ; Schappin R; Nijsten TEC; Veen JCCMI'; Braunstahl GJ; Hijnen D
    Clin Transl Allergy; 2024 Aug; 14(8):e12386. PubMed ID: 39152529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Facial and neck erythema associated with dupilumab treatment: A systematic review.
    Jo CE; Finstad A; Georgakopoulos JR; Piguet V; Yeung J; Drucker AM
    J Am Acad Dermatol; 2021 May; 84(5):1339-1347. PubMed ID: 33428978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.